Daiichi takes mRNA COVID-19 vaccine into clinic as Japanese R&D belatedly fires up

Daiichi Sankyo has begun (PDF) a phase 1/2 clinical trial of an mRNA vaccine against COVID-19. The vaccine is set to come to market well after leading prophylactics but gives Japan a chance to establish its own countermeasures for COVID-19 and future health crises.